Johnson & Johnson Resets Device Business with ACUVUE Approval and Laminar Transfer
Johnson & Johnson (JNJ) has received CE Marking in Europe for its ACUVUE OASYS MAX reusable contact lenses, designed specifically for digital device users. This approval marks a significant move by the company to refresh established franchises and focus on next-generation products.
The same day, Jaguar LAA, Inc. announced that it would acquire Johnson & Johnson's Laminar left atrial appendage closure program assets from its MedTech portfolio. This transfer will shift development of the left atrial appendage closure device to Jaguar LAA, while Johnson & Johnson reallocates resources.
The ACUVUE OASYS MAX approval and Laminar divestment are part of a broader story at Johnson & Johnson. The company is expanding within MedTech, driven by strong performance from acquired cardiovascular units Abiomed and Shockwave, as well as developments in robotic surgery.
The Narrative leans on higher returns from next-generation medicines and devices, while older products and tariffs pull the other way. Every portfolio tweak inside MedTech matters, testing whether management is concentrating capital where that thesis expects it to show up.